Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity

European Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2010, Pages 1295-1303

  Czopek, Anna ^a   Byrtus, Hanna ^a   Kołaczkowski, Marcin ^a   Pawłowski, Maciej ^a   Dybała, Małgorzata ^a   Nowak, Gabriel ^a   Tatarczyńska, Ewa ^b   Wesołowska, Anna ^a,b   Chojnacka Wójcik, Ewa ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressants; Anxiolytics; Imidazolidine 2,4 diones; Pre and postsynaptic 5 HT1A receptor agonists

Indexed keywords

1 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL] 2',3' DIHYDROSPIRO[IMIDAZOLINE 4,1' INDENE] 2,5 DIONE; 1 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL] 3',4' DIHYDRO 2'H SPIRO[IMIDAZOLINE 4,1' NAPHTHALENE] 2,5 DIONE; 1 [3 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 2',3' DIHYSPIRO[IMIDAZOLINE 4,1' INDENE] 2,5 DIONE; 1 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL] 2',3' DIHYSPIRO[IMIDAZOLINE 4,1' INDENE] 2,5 DIONE; 1 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL] 3',4' DIHYDRO 2'H SPIRO[IMIDAZOLINE 4,1' NAPHTHALENE] 2,5 DIONE; 1 [3 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3',4' DIHYDRO 2'H SPIRO[IMIDAZOLINE 4,1' NAPHTHALENE] 2,5 DIONE; 5 CYCLOPROPYL 5 PHENYL 3 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]IMIDAZOLINE 2,4 DIONE; 5 CYCLOPROPYL 5 PHENYL 3 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]IMIDAZOLINE 2,4 DIONE; 5 CYCLOPROPYL 5 PHENYL 3 [3 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL]IMIDAZOLINE 2,4 DIONE; 5 METHYL 5 PHENYL 3 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]IMIDAZOLINE 2,4 DIONE; 5 METHYL 5 PHENYL 3 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]IMIDAZOLINE 2,4 DIONE; 5 METHYL 5 PHENYL 3 [3 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL]IMIDAZOLINE 2,4 DIONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; HYDANTOIN DERIVATIVE; IMIPRAMINE; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; LOCOMOTION; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SWIMMING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; IMIDAZOLIDINES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS;

EID: 77349102450     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.11.053     Document Type: Article

References (45)

1. Barnes N.M., and Sharp T. Neuropharmacology 38 (1999) 1083-1152
2. Oh S.J., Ha H.J., Chi D.Y., and Lee H.K. Curr. Med. Chem. 8 (2001) 999-1034
3. Blier P., and Ward N.M. Biol. Psychiatry 53 (2003) 193-203
4. Muller C.P., Carey R.J., Huston J.P., and De Souza Silva M.A. Prog. Neurobiol. 81 (2007) 133-178
5. Lopez-Rodriguez M.L., Ayala D., Benhamu B., Morcillo M.J., and Viso A. Curr. Med. Chem. 9 (2002) 443-469
6. Caliendo G., Santagada V., Perissutti E., and Fiorino F. Curr. Med. Chem. 12 (2005) 1721-1753
7. Jordan S., Chen R., Koprivica V., Hamiltona R., Whitehead R.E., Tottori K., and Kikuchi T. Eur. J. Pharmacol. 517 (2005) 165-173
8. Hughes Z.A., Starr K.R., Langmead C.J., Hill M., Bartoszyk G.D., Hagen J.J., Middlemiss D.N., and Dawson L.A. Eur. J. Pharmacol. 510 (2005) 49-57
9. Feiger A.D., Heiser J.F., Shrivastava R.K., Weiss K.J., Smith W.T., Sitsen J.M., and Gibertini M. J. Clin. Psychiatry 64 (2003) 243-249
10. Iwasaki Y., Shiojima T., Kinoshita M., and Ikeda K. J. Neurol. Sci. 160 (1998) 92-96
11. Byrtus H., Pawłowski M., Czopek A., Bojarski A.J., Duszyńska B., Nowak G., Kłodzińska A., Taterczyńska E., Wesołowska A., and Chojnacka-Wójcik E. Eur. J. Med. Chem. 40 (2005) 820-829
12. Byrtus H., Pawłowski M., Duszyńska B., Wesołowska A., Chojnacka-Wójcik E., and Bojarski A.J. Pol. J. Pharmacol. 53 (2001) 395-401
13. Goodson L.H., Honigberg J.L., Lehman J.L., and Burton W.H. J. Org. Chem. 25 (1960) 1920-1924
14. Middlemiss D.N., and Fozard J.R. Eur. J. Pharmacol. 90 (1983) 151-153
15. Leysen J.E., Niemegers C.J., Van Neuten J.M., and Laduron P.M. Mol. Pharmacol. 21 (1982) 301-314
16. Ossowska G., Nowak G., Kata R., Klenk-Majewska B., Danilczuk Z., and Żebrowska-Łupina I. J. Neural Transm. 108 (2001) 311-314
17. Goodwin G.M., De Souza R.J., and Green A. Neuropharmacology 24 (1985) 1187-1194
18. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., and Fletcher A. Eur. J. Pharmacol. 281 (1995) 81-88
19. Berendsen H.H.G., Jenck F., and Broekkamp C.L.E. Pharmacol., Biochem. Behav. 33 (1989) 821-827
20. Berendsen H.H.G., Broekkamp C.L.E., and van Delft A.M.L. Behav. Neural Biol. 55 (1991) 214-226
21. Darmani N.A., Martin B.R., Pandey U., and Glennon R.A. Pharmacol., Biochem. Behav. 36 (1990) 901-906
22. Willins D.L., and Meltzer H.Y. J. Pharmacol. Exp. Ther. 282 (1997) 699-706
23. Porsolt R.D., Bertin A., and Jalfre M. Arch. Int. Pharmacodyn 229 (1977) 327-336
24. Aron C., Simon P., Larousse C., and Boissier J.R. Neuropharmacology 10 (1971) 459-469
25. Deakin J.F.W. J. Psychopharmacol. 7 (1993) 283-289
26. Schreiber R., and De Vry J. Prog. Neuropsychopharmacol. Biol. Psychiatry 17 (1993) 87-104
27. De Vry J. Psychopharmacology 121 (1995) 1-26
28. Griebel G., Blanchard D.C., Rettori M.C., Guardiola-Lemaitre B., and Blanchard R.J. Pharmacol., Biochem. Behav. 54 (1996) 509-516
29. Dereń-Wesołek A., Tatarczyńska E., and Chojnacka-Wójcik E. J. Psychopharmacol. 12 (1998) 380-384
30. Wesołowska A., Paluchowska M.H., Gołembiowska K., and Chojnacka-Wójcik E. J. Pharm. Pharmacol. 55 (2003) 533-543
31. Millan M.J. Prog. Neurobiol. 70 (2003) 83-244
32. Stader C.D., Candelore M.R., Hill W.S., Dixon R.A., and Sigal I.S. J. Biol. Chem. 264 (1989) 16470-16477
33. Strader C.D., Sigal I.S., and Dixon R.A. FASEB J. 3 (1989) 1825-1832
34. Ho Y.B., Karschin A., Branchek T., Davidson N., and Lester H.A. FEBS Lett. 312 (1992) 259-262
35. Strader C.D., Sigal I.S., Candelore M.R., Rands E., Hill W.S., and Dixon R.A. J. Biol. Chem. 263 (1988) 10267-10271
36. Liapakis G., Ballesteros J.A., Parachristou S., Chan W.C., Chen X., and Javitch J.A. J. Biol. Chem. 275 (2000) 37779-37788
37. Choudhary M.S., Craigo S., and Roth B.L. Mol. Pharmacol. 43 (1993) 755-761
38. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. Science 318 (2007) 1258-1265
39. Kołaczkowski M., Nowak M., Pawłowskie M., and Bojarski A.J. J. Med. Chem. 49 (2006) 6732-6741
40. Nowak M., Kołaczkowski M., Pawłowski M., and Bojarski A.J. J. Med. Chem. 49 (2006) 205-214
41. Lopez-Rodriguez M.L., Morcillo M.J., Fernandez E., Rosado M.L., Pardo L., and Schaper K. J. Med. Chem. 44 (2001) 198-207
42. Lopez-Rodriguez M.L., Vicente B., Deupi X., Barrondo S., Olivella M., and Morcillo M.J. Mol. Pharmacol. 62 (2002) 15-21
43. Lopez-Rodriguez M.L., Morcillo M., Fernandez E., Benhamu B., Tejada I., Ayala D., Viso A., Olivella M., Pardo L., Delgado M., Manzanares J., and Fuentes J.A. J. Med. Chem. 48 (2005) 2548-2558
44. Rarey M., Kramer B., Lengauer T., and Klebe G. J. Mol. Biol. 261 (1996) 470-489
45. Evers A., and Klabunde T. J. Med. Chem. 48 (2005) 1088-1097